{"title":"A new progestagen for oral contraception.","authors":"E De Jager","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Desogestrel (13-ethyl-11-methylene-18, 19-dinor-17alpha-pregn-4-en-20-yn-17-ol) is a new potent progestagen suitable for incorporation into combined oral contraceptives (OC)s. 2 products have thus far been developed, 1 containing 150 mcg desogestrel plus 30 mcg ethinyl estradiol (EE)/tablet (Marvelon) and the other a normophasic product containing 50 mcg EE (7 tablets) followed by 125 mcg desogestrel plus 50 mcg EE (15 tablets). No tablet failures were reported in large-scale multicenter trials. Clinical studies, confirmed by receptor studies, showed that desogestrel lacks androgenicity in the dosages used. Also, studies on lipid metabolism revealed that desogestrel does not abolish EE-induced rises in HDL cholesterol. Since low levels of HDL cholesterol have been associated with an increased risk of ischemic heart disease, this can be regarded as a favorable aspect of desogestrel. In view of increasing demands for safer OCs, it can be concluded that preference should be given to OCs containing this progestogen.</p>","PeriodicalId":84493,"journal":{"name":"Contraceptive delivery systems","volume":"3 1","pages":"11-5"},"PeriodicalIF":0.0000,"publicationDate":"1982-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Contraceptive delivery systems","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Desogestrel (13-ethyl-11-methylene-18, 19-dinor-17alpha-pregn-4-en-20-yn-17-ol) is a new potent progestagen suitable for incorporation into combined oral contraceptives (OC)s. 2 products have thus far been developed, 1 containing 150 mcg desogestrel plus 30 mcg ethinyl estradiol (EE)/tablet (Marvelon) and the other a normophasic product containing 50 mcg EE (7 tablets) followed by 125 mcg desogestrel plus 50 mcg EE (15 tablets). No tablet failures were reported in large-scale multicenter trials. Clinical studies, confirmed by receptor studies, showed that desogestrel lacks androgenicity in the dosages used. Also, studies on lipid metabolism revealed that desogestrel does not abolish EE-induced rises in HDL cholesterol. Since low levels of HDL cholesterol have been associated with an increased risk of ischemic heart disease, this can be regarded as a favorable aspect of desogestrel. In view of increasing demands for safer OCs, it can be concluded that preference should be given to OCs containing this progestogen.